Tackling Chronic Disease with Cell and Gene Therapies
Presented by SGInnovate
The repair of old, damaged, or diseased tissues using gene or cell therapies promises a future where people live longer, healthier lives. According to a McKinsey study, recent years have seen a steady acceleration in the number of cell and gene therapies (CGTs) on the market – more than 75 have been launched (including launches in individual markets, such as Japan, Russia, and South Korea) by the end of 2019. Many more are in development, offering the hope of revolutionary healthcare.
Yet, despite such early promise, the extent to which scientific breakthroughs in CGT will translate into similar advances in healthcare remains uncertain. The adoption of CGT faces almost the same challenges everywhere – technical issues, high costs, and concerns about long-term safety, for example.
In this session, our panel of thought leaders will be sharing their insights on the significance of using 'living drugs' as a therapeutic, the key considerations in its application and manufacturing, patient and public perspectives on CGTs, and the market opportunities and challenges.
Date: 1 September 2022, Thursday
Time: 11:00am – 12:00pm (Singapore Time / UTC +8)
11:00am – 11:05am: Introduction and Welcome
11:05am – 12:00pm: Panel Discussion and Q&A on Tackling Chronic Disease with Cell and Gene Therapies
Topics: MedTech / HealthTech / BioTech
Industry: Health and BioMedical Sciences